Dual-action drug candidate seeks to regulate metabolic profile and reduce inflammation

Pharmacology
–

Metabolic syndrome

They are investigating a pan-PPAR agonist in metabolic syndrome that, due to its different mechanisms, can reduce the number of drugs consumed and adherence problems.

Incliva researchers Carlos Villarroel-Vicente, Patrice Marques, Laura Piqueras, María Jesús Sanz, Nuria Cabedo, Laura Vila, Ainhoa ​​García and Álvaro Bernabeu. Photo: INCLIVA